{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:33:54Z","timestamp":1768070034749,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.vaccine.2004.11.040","type":"journal-article","created":{"date-parts":[[2004,12,9]],"date-time":"2004-12-09T17:58:50Z","timestamp":1102615130000},"page":"2689-2695","source":"Crossref","is-referenced-by-count":58,"title":["Review on flavivirus vaccine development"],"prefix":"10.1016","volume":"23","author":[{"given":"J.","family":"Hombach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Cardosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Deubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kurane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.T.","family":"Roehrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sabchareon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Kieny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.11.040_bib1","unstructured":"WHO Initiative for Vaccine Research. www.who.int\/vaccine_research\/en\/. Accessed 9.8.2004."},{"issue":"1","key":"10.1016\/j.vaccine.2004.11.040_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1473-3099(01)00171-2","article-title":"Dengue: an update","volume":"2","author":"Guzman","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2004.11.040_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/382280","article-title":"Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand","volume":"189","author":"Endy","year":"2004","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2004.11.040_bib4","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1128\/JVI.76.7.3318-3328.2002","article-title":"Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys","volume":"76","author":"Markoff","year":"2002","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2004.11.040_bib5","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2004.11.040_bib6","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1128\/JVI.78.5.2367-2381.2004","article-title":"Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses","volume":"78","author":"Keelapang","year":"2004","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2004.11.040_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"6 Suppl.","key":"10.1016\/j.vaccine.2004.11.040_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine","volume":"69","author":"Edelman","year":"2003","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.vaccine.2004.11.040_bib9","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"issue":"27\u201330","key":"10.1016\/j.vaccine.2004.11.040_bib10","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/S0264-410X(03)00488-2","article-title":"Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys","volume":"21","author":"Whitehead","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2004.11.040_bib11","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/JVI.77.2.1653-1657.2003","article-title":"A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3\u2032 untranslated region is highly attenuated and immunogenic in monkeys","volume":"77","author":"Whitehead","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2004.11.040_bib12","unstructured":"Pediatric Dengue Vaccine Initiative. www.pdvi.org\/default.asp, accessed 9.8.2004."},{"issue":"8","key":"10.1016\/j.vaccine.2004.11.040_bib13","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2004.11.040_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0264-410X(00)00038-4","article-title":"Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines","volume":"18","author":"Markoff","year":"2000","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2004.11.040_bib15","first-page":"334","article-title":"Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China","volume":"81","author":"Ding","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2004.11.040_bib16","unstructured":"Children's Vaccine Program at PATH. www.childrensvaccine.org\/html\/jep.htm, accessed 9.8.2004."},{"issue":"8","key":"10.1016\/j.vaccine.2004.11.040_bib17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/14712598.4.8.1295","article-title":"West Nile virus vaccines","volume":"4","author":"Hall","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2004.11.040_bib18","unstructured":"Yellow Fever vaccine: WHO position paper. Weekly Epidemiological Records. 2003;78:349\u2013359."},{"key":"10.1016\/j.vaccine.2004.11.040_bib19","unstructured":"Guidelines for the evaluation of dengue vaccines in populations exposed to natural infection. TDR\/IVR\/DEN\/02.1. www.who.int\/tdr\/publications\/publications\/dengueguidelines.htm, accessed 9.8.2004."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04008849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04008849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T19:51:16Z","timestamp":1548964276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04008849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":19,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0264410X04008849"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.11.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}